Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DEP salvage therapy for refractory EBV-associated hemophagocytic lymphohistiocytosis
ChiCTR-OPC-15007481Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaspargase, pegylated liposomal doxorubicin, etoposide and methylprednisolone in Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH), sponsored by Beijing Friendship Hospital. Primary endpoints: white blood cell count, neutrophil count and 11 more. Started Dec 2015; status: recruiting.
02
Drugs
pegaspargasepegylated liposomal doxorubicinetoposidemethylprednisolone
03
Conditions
Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH)
Beyond the preview
Go deeper on ChiCTR-OPC-15007481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007481.